Alkem’s business model encompasses a wide range of therapeutic segments, including anti-infectives, dermatology, and chronic therapies like diabetology and cardiology, supported by a substantial portfolio exceeding 800 brands. This diversified product mix mitigates risk and caters to varied market demands. The company’s operational strength is underpinned by a significant manufacturing footprint, comprising 21 facilities, the majority of which are located in India, providing a cost-competitive production base.
From a market positioning standpoint, Alkem holds a strong standing within the Indian pharmaceutical landscape, consistently ranking among the top players in terms of domestic sales. The company’s growth trajectory has been fueled by organic expansion through investments in manufacturing and research and development, as well as inorganic growth via strategic acquisitions. Alkem’s commitment to R&D underscores its focus on new product development and maintaining a competitive edge. As a publicly listed entity since 2015, Alkem operates with a focus on delivering shareholder value through sustained growth and profitability within the dynamic pharmaceutical sector.
Latest News on ALKEM Laboratories
Delhi High Court bars Alchem International from utilizing the ‘ALCHEM’ trademark for pharmaceutical retail products.
Alkem Laboratories, one of India’s largest pharmaceutical companies, has been embroiled in a trademark dispute with Alchem International, a manufacturer of plant-derived active ingredients and Ayurvedic extracts. The controversy centers around the use of the marks “ALKEM” and “ALCHEM”, with Alkem claiming that Alchem’s increasing use of its mark is likely to cause confusion and amounts to trademark infringement and passing off. Alkem has been using its mark since its incorporation in 1973 and holds multiple trademark registrations, with the earliest dating back to October 1973.
Alchem, on the other hand, began using its mark in 1985, asserting that it was coined from the words “Alkaloids and Chemicals”. The company argues that Alkem’s suit is barred by delay and acquiescence, as Alkem was aware of its business for decades and took no action after sending a cease-and-desist notice in 2005. Alchem also contends that its operations, focused on nutraceuticals and herbal extracts, are distinct from Alkem’s prescription drug business.
Furthermore, Alchem relies on a 1990 Bombay High Court order that refused interim relief to Alkem in an earlier dispute involving another entity using the “Alchem” name. This, Alchem argues, demonstrates that Alkem’s mark lacked reputation at the time. Additionally, Alchem maintains that its use of the mark for exports and Active Pharmaceutical Ingredients (API) manufacture since 1985 constitutes honest and concurrent use.
The dispute highlights the complexities of trademark law, particularly in cases where similar marks are used by different companies operating in related but distinct fields. The outcome of the case will depend on the court’s assessment of the likelihood of confusion, the reputation of Alkem’s mark, and the validity of Alchem’s defenses. The case also raises questions about the implications of delay and acquiescence in trademark disputes, as well as the scope of honest and concurrent use. Ultimately, the court’s decision will have significant implications for the pharmaceutical industry in India and the protection of intellectual property rights.
Alkem Laboratories encounters conflicting technical indicators as promoter confidence wanes.
Alkem Laboratories, a midcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its evaluation score due to changes in technical trends. The company’s technical indicators present a mixed picture, with the MACD showing bullish signals on a weekly basis but mildly bearish on a monthly scale. The Relative Strength Index (RSI) indicates bearish conditions weekly, while the monthly data shows no significant signal. This mixed performance is reflected in the company’s market returns, with a -12.29% return over the past year, despite a 4.9% increase in profits during the same timeframe.
Despite the challenges, Alkem Laboratories maintains strong management efficiency, with a return on equity (ROE) of 17.69% and a low debt-to-equity ratio of 0 times. However, the company faces declining promoter confidence, with stakeholders reducing their holdings by 2.09% in the last quarter. This trend may reflect concerns regarding the company’s long-term growth prospects, particularly as net sales and operating profit have shown modest annual growth rates over the past five years.
The company’s financial performance is a mixed bag, with strong management efficiency and low debt, but modest growth in net sales and operating profit. The decline in promoter confidence is a concern, as it may indicate a lack of faith in the company’s long-term prospects. Overall, Alkem Laboratories’ adjusted evaluation score reflects the changes in technical trends and the mixed performance of the company. The company’s future growth prospects will depend on its ability to address the challenges it faces and improve its financial performance.
The mixed technical indicators and declining promoter confidence suggest that investors should exercise caution when considering Alkem Laboratories as an investment opportunity. However, the company’s strong management efficiency and low debt make it an attractive option for investors looking for a stable and well-managed company. Ultimately, the decision to invest in Alkem Laboratories will depend on an individual’s investment goals and risk tolerance. It is essential to conduct thorough research and analysis before making any investment decisions.
Alkem introduces a biosimilar version of Pertuzumab in the Indian market.
Alkem Laboratories has launched a biosimilar version of pertuzumab, a monoclonal antibody used in the treatment of early and metastatic breast cancer, in the Indian market. The company’s product is a rival to Roche’s Perjeta, a widely used pertuzumab-based medication. According to Alkem, its pertuzumab biosimilar “meets global standards” of quality, safety, and efficacy.
Pertuzumab is used in combination with other medications, such as trastuzumab and docetaxel, to treat patients with HER2-positive breast cancer. The introduction of Alkem’s biosimilar is expected to increase accessibility and affordability of this life-saving medication for Indian patients. The company has emphasized that its product has undergone rigorous testing and has demonstrated comparable quality, safety, and efficacy to the reference product, Perjeta.
The launch of Alkem’s pertuzumab biosimilar is significant, as it has the potential to disrupt the Indian market for breast cancer treatments. Perjeta, the reference product, is a costly medication, and the introduction of a biosimilar is expected to lead to increased competition and lower prices. This, in turn, is likely to benefit patients, who will have access to a more affordable treatment option.
Alkem’s pertuzumab biosimilar has been approved by the Indian regulatory authorities, and the company has stated that it will be made available at a “competitive price” in the market. The company has also emphasized its commitment to providing high-quality, affordable medications to patients in India and globally.
The launch of Alkem’s pertuzumab biosimilar is part of a larger trend of biosimilar introductions in the Indian market. In recent years, several Indian pharmaceutical companies have launched biosimilars of popular medications, including trastuzumab, bevacizumab, and rituximab. These introductions have increased competition and led to lower prices, making these medications more accessible to patients.
Overall, the launch of Alkem’s pertuzumab biosimilar is a positive development for Indian patients with breast cancer. The introduction of this affordable treatment option is expected to improve access to life-saving medication and increase competition in the market, ultimately benefiting patients and the healthcare system as a whole.
Alkem Laboratories Receives ₹35.11 Crore GST Notice for Claiming Input Tax Credit Twice
Alkem Laboratories Limited, a leading Indian pharmaceutical company, has received an order from the GST authorities confirming a tax demand of over Rs. 35 crore. The order, passed by the Commissioner (Appeals) – II, CGST and Central Excise, Mumbai, relates to the period from July 2017 to March 2022 and includes a penalty of Rs. 3.51 crore and applicable interest. The dispute centers on Input Tax Credit (ITC), which allows businesses to reduce their tax liability on sales by claiming credit for taxes already paid on inputs.
The GST department alleges that Alkem claimed ITC twice in its monthly return filings, while the same credits were not reflected in the government’s reconciliation statement. As a result, the department denied the ITC and raised the demand. Alkem Laboratories disagrees with the findings and plans to contest the order through appropriate legal action, including filing an appeal. The company believes it has strong factual and legal grounds to defend its case.
Despite the tax demand, Alkem Laboratories does not expect an immediate cash outflow, as it has a sufficient input tax credit balance available, apart from the disputed amount. This means the company can adjust the liability if required while continuing to fight the case through legal remedies. The outcome of this GST dispute will now depend on the company’s appeal and further legal proceedings.
Alkem Laboratories is known for its wide range of generic and branded medicines and is one of India’s leading pharmaceutical companies. The company has stated that there is no material impact on its financial or operational performance as a result of the order. The case highlights the importance of accurate and transparent reporting of ITC claims to avoid disputes with tax authorities.
The GST department’s order may have implications for other companies that claim ITC, and it is essential for businesses to ensure that their ITC claims are accurate and reflected in the government’s reconciliation statement. Alkem Laboratories’ decision to contest the order and appeal the decision may provide clarity on the interpretation of ITC rules and regulations. The outcome of this case will be closely watched by the pharmaceutical industry and tax experts.
Alkem Laboratories has allocated INR 100 crore for the establishment of a state-of-the-art radiotherapy centre in Muzaffarpur.
Alkem Laboratories, a prominent pharmaceutical company, has made a significant investment of INR 100 crore in a new radiotherapy centre located in Muzaffarpur, Bihar. This substantial investment underscores the company’s commitment to expanding its presence in the healthcare sector and providing advanced medical facilities to patients.
The radiotherapy centre, equipped with state-of-the-art technology, aims to provide comprehensive cancer treatment services to patients in the region. By investing in this centre, Alkem Laboratories is addressing the growing need for cancer care services in India, particularly in rural and semi-urban areas where access to quality healthcare is often limited.
The new centre will offer a range of services, including radiation therapy, chemotherapy, and surgical oncology, catering to the diverse needs of cancer patients. With the establishment of this centre, Alkem Laboratories is poised to make a positive impact on the lives of patients and their families, providing them with access to world-class cancer treatment facilities.
This investment is also expected to generate employment opportunities in the region, contributing to the local economy and promoting overall development. The centre will create jobs for medical professionals, technicians, and support staff, thereby boosting the local job market and fostering growth.
Alkem Laboratories’ decision to invest in a radiotherapy centre in Muzaffarpur demonstrates the company’s focus on promoting healthcare infrastructure in tier-II and tier-III cities. By doing so, the company is bridging the gap in healthcare services between urban and rural areas, ensuring that patients in these regions have access to quality medical care.
The investment of INR 100 crore in the radiotherapy centre is a testament to Alkem Laboratories’ commitment to the healthcare sector and its dedication to improving the lives of patients. As the company continues to expand its presence in the healthcare industry, it is likely to make a significant impact on the lives of people in India, particularly in regions where access to quality healthcare is limited.
Overall, Alkem Laboratories’ investment in the new radiotherapy centre in Muzaffarpur is a positive step towards promoting healthcare infrastructure and providing advanced medical facilities to patients in the region. The company’s commitment to the healthcare sector is expected to have a lasting impact on the lives of people in India, and its efforts to expand access to quality healthcare services are commendable.
Stock Market Updates for ALKEM Laboratories
Recent Updates
Alkem Foundation backs the setup of North Bihar’s biggest radiotherapy facility, located in Muzaffarpur.
Alkem Foundation, the corporate social responsibility arm of Alkem Laboratories Ltd., has invested INR 100 crores in the establishment of the Samprada Singh Memorial Radiotherapy Centre in Muzaffarpur, Bihar. This state-of-the-art facility is part of the newly inaugurated Homi Bhabha Cancer Hospital and Research Centre and has the capacity to treat 3,500-4,000 cancer patients annually, making it the largest in North Bihar and the second-largest in the state.
The centre is equipped with advanced technologies, including linear accelerators, stereotaxy, and in-house brachytherapy, and has been developed in collaboration with the Tata Memorial Centre in Mumbai. The goal of this centre is to provide world-class cancer treatment options to patients in Bihar and neighboring states, bridging the gap in cancer treatment in these regions.
According to Madhurima Singh, Executive Director of Alkem, the company has its roots in Bihar and is committed to giving back to the region. With cancer cases on the rise, the need for advanced facilities is greater than ever. The centre will not only provide treatment but also support patients and their families, creating a holistic model of care.
The partnership between Alkem Foundation and the Homi Bhabha Cancer Hospital and Research Centre builds on years of collaboration in screening and palliative care. The centre aims to provide complete and compassionate cancer care, including ethical and affordable evidence-based treatment, as well as education and research.
This initiative is part of Alkem Foundation’s existing cancer care programs, which include screening, awareness, and home-based palliative care. The foundation’s goal is to strengthen healthcare infrastructure and bridge treatment gaps in underserved regions. With the establishment of the Samprada Singh Memorial Radiotherapy Centre, Alkem Foundation is taking a significant step towards providing sustainable healthcare solutions that have a lasting impact on the community.
Muzaffarpur set to receive a Rs 100 crore radiotherapy center: Rediff Money News
A new radiotherapy center is being developed in Muzaffarpur, Bihar, with an investment of Rs 100 crore by Alkem Laboratories. The center, named Samprada Singh Memorial Radiotherapy Centre, will be part of the Homi Bhabha Cancer Hospital and Research Centre (HBCHRC), which was recently inaugurated by Prime Minister Narendra Modi. The radiotherapy center aims to treat 3,500-4,000 patients every year, addressing the growing need for cancer treatment facilities in the region.
The center is named after Alkem’s late founder, who hailed from Bihar, and is a testament to the company’s commitment to giving back to the community. According to Alkem’s Executive Director, Madhurima Singh, the company has its roots in Bihar, and it is meaningful for them to contribute to the region, especially with the rising cases of cancer. The partnership between Alkem and HBCHRC builds on years of collaboration in screening and palliative care, and the new center will provide complete and compassionate cancer care to patients in Bihar and neighboring states.
The development of the radiotherapy center is a significant step towards bridging the gap in cancer treatment in the region. With the rising incidence of cancer, there is a growing need for world-class facilities that can provide comprehensive care to patients. The center will be equipped with state-of-the-art technology and will provide treatment to patients from Bihar and neighboring states. The partnership between Alkem and HBCHRC is expected to have a significant impact on the healthcare landscape of the region, providing much-needed access to cancer treatment and care.
The investment of Rs 100 crore by Alkem Laboratories is a significant commitment to the development of the radiotherapy center. The company’s contribution will help to establish a world-class facility that will provide treatment to thousands of patients every year. The center will be a major boost to the healthcare infrastructure of the region, and will help to address the growing need for cancer treatment facilities. Overall, the development of the Samprada Singh Memorial Radiotherapy Centre is a significant step towards improving cancer care in Bihar and neighboring states.
Alkem Laboratories (NSE:ALKEM) appears to be in a strong position to handle its debt obligations.
Warren Buffett’s quote, “Volatility is far from synonymous with risk,” highlights the importance of considering debt when assessing a company’s risk. Alkem Laboratories Limited (NSE:ALKEM) carries debt, but the question remains whether this debt makes the company risky. To determine this, it’s essential to consider the company’s cash and debt together. As of March 2025, Alkem Laboratories had ₹13.8b in debt, which is offset by ₹41.0b in cash, resulting in ₹27.2b in net cash.
The company’s balance sheet shows that it has ₹39.6b in liabilities due within a year and ₹12.9b due beyond that. However, it also has ₹41.0b in cash and ₹25.9b in receivables due within a year, resulting in ₹14.4b more liquid assets than total liabilities. This short-term liquidity indicates that Alkem Laboratories could easily pay off its debt, and its balance sheet is not stretched. The company’s net cash position and ability to convert earnings before interest and tax (EBIT) to free cash flow, which has been around 75% over the last three years, put it in a good position to manage its debt.
Alkem Laboratories’ debt does not appear to be a significant risk, given its net cash position and decent-looking balance sheet. The company’s ability to generate free cash flow and its growth in EBIT by 4.4% in the last year also make its debt load more manageable. While it’s always important to investigate a company’s debt, Alkem Laboratories’ situation does not seem to pose a significant risk. However, it’s essential to consider other factors, such as the company’s overall financial health and potential risks that may not be immediately apparent from the balance sheet.
In conclusion, Alkem Laboratories’ debt is not a significant concern, given its net cash position, ability to generate free cash flow, and decent-looking balance sheet. The company’s growth in EBIT and its ability to convert earnings to free cash flow also contribute to its relatively low-risk debt profile. However, it’s crucial to continue monitoring the company’s financial health and potential risks to ensure that its debt remains manageable.
Alkem Laboratories injects $70 million into the US market, leveraging its Enzene capabilities.
Enzene Biosciences, a biotech subsidiary of Alkem Labs, one of India’s top five pharmaceutical companies, has launched a new manufacturing facility in the US. The facility, located in New Jersey, has been established with an investment of $70 million. This move follows President Donald Trump’s calls to pharmaceutical companies to increase local manufacturing and create employment opportunities. Currently, the facility has hired 50 people, with plans to expand its workforce to 200 employees over time.
According to Himanshu Gadgil, CEO of Enzene Biosciences, the company has developed a connected continuous manufacturing technology, known as EnzeneX, which offers significant cost efficiencies and faster processing compared to traditional batch-wise biotech drug manufacturing. This technology has been developed indigenously by Enzene and is now being implemented in the US facility.
Gadgil sees this development as a reflection of Enzene’s growth and the strength of India’s scientific ecosystem. He believes that this technology has the potential to contribute transformative solutions to the world. The establishment of the US facility is a significant milestone for Enzene, marking its expansion into the global market.
The connected continuous manufacturing technology developed by Enzene is expected to revolutionize the biotech drug manufacturing process. By offering cost efficiencies and faster processing, this technology has the potential to increase the availability of biotech drugs and reduce their costs. The implementation of this technology in the US facility is expected to have a positive impact on the global biotech industry.
Overall, Enzene’s launch of its US manufacturing facility is a significant development in the biotech industry. The company’s investment in the US market and its commitment to developing innovative technologies are expected to drive growth and expansion in the years to come. With its strong foundation in India and its expanding presence in the global market, Enzene Biosciences is poised to become a major player in the biotech industry.
Alkem Laboratories Sees Varied Results as Stakeholders Raise Concerns and Assessment Criteria Evolve
Alkem Laboratories, a midcap company in the Pharmaceuticals & Biotechnology sector, has undergone an evaluation adjustment due to changes in its underlying trends. The company’s financial performance is mixed, with a year-over-year return of -7.52% and a modest profit increase of 4.9%. Despite this, the company’s net sales growth has averaged 9.38% annually over the last five years, with operating profit growth at 9.03%. However, the recent quarter’s results have shown flat performance, raising concerns about long-term growth potential.
Promoter confidence in the company appears to be decreasing, with a 2.09% decrease in their stake, which now stands at 53.04%. This decline may indicate concerns about the company’s future trajectory. On the other hand, Alkem Laboratories maintains a high management efficiency, with a return on equity (ROE) of 17.69% and a low debt-to-equity ratio of 0 times. This suggests that the company is being managed effectively, despite the challenges it faces.
The recent evaluation adjustment reflects the complexities of Alkem Laboratories’ market position and performance indicators. The company’s mixed financial performance, combined with the decline in promoter confidence, raises questions about its long-term growth potential. However, the company’s high management efficiency and low debt-to-equity ratio are positive indicators that suggest it may be able to navigate these challenges.
Overall, Alkem Laboratories is facing a complex market position, with both positive and negative indicators. The company’s mixed financial performance and declining promoter confidence are concerns, but its high management efficiency and low debt-to-equity ratio are positives. As the company continues to navigate these challenges, it will be important to monitor its performance and adjust expectations accordingly. With the latest evaluation adjustment, it is essential for investors to reassess the company’s potential and make informed decisions about their investments.
Meet India’s oldest billionaire, owner of Alkem Labs, who proudly owns a luxurious multi-crore Rolls Royce Cullinan.
India’s oldest billionaire, Samprada Singh, has become the proud owner of a brand-new Rolls-Royce Cullinan. At 93 years old, Singh is not only the oldest man in India to own this luxury vehicle, but he is also the billionaire owner of Alkem Labs, a leading pharmaceutical company in the country.
The Rolls-Royce Cullinan is a highly sought-after luxury SUV that is priced around Rs 6.95 crore in India, making it one of the most expensive cars available in the market. This luxury vehicle is known for its exceptional performance, luxurious features, and sleek design.
Singh’s new acquisition is a testament to his success and wealth, which he has accumulated over the years through his pharmaceutical business. As the owner of Alkem Labs, Singh has built a business empire that has made him one of the richest men in India.
Alkem Labs is a well-established company that specializes in the development, manufacture, and marketing of pharmaceutical products. The company has a strong presence in India and exports its products to several countries around the world. Under Singh’s leadership, Alkem Labs has experienced significant growth and has become one of the leading pharmaceutical companies in India.
Singh’s achievement is not only a reflection of his business acumen but also his passion for luxury and high-end products. The acquisition of the Rolls-Royce Cullinan is a statement of his success and his ability to indulge in the finer things in life.
The video showcasing Singh’s new car has gone viral on social media, with many people congratulating him on his new acquisition. netizens are praising Singh’s enthusiasm and passion for luxury cars, even at the age of 93.
Overall, Samprada Singh’s acquisition of the Rolls-Royce Cullinan is a testament to his success, wealth, and passion for luxury. As the oldest billionaire in India, Singh continues to inspire and motivate people with his achievements and his love for the finer things in life. His story serves as a reminder that age is just a number, and with hard work and determination, anything is possible.
It will be interesting to see how Singh enjoys his new luxury vehicle and how he continues to build his business empire in the years to come. As a role model for many, Singh’s achievements are a source of inspiration, and his love for luxury cars is a reflection of his success and prosperity.
Alkem Laboratories’ Sarvesh Singh purchases luxurious Mumbai property worth Rs 174 crore, see details
The luxury property market in Mumbai, India’s financial capital, is experiencing a surge in demand, with over Rs 800 crore worth of high-end property deals recorded in February and March alone. Affluent individuals, including business leaders and celebrities, are driving this trend. One notable example is Sarvesh Singh, executive director of Alkem Laboratories, who recently acquired a sea-facing duplex in Bandra’s Supreme ArtHouse for Rs 174 crore. The 12,148 square foot property offers breathtaking views of the Arabian Sea and is considered one of the most expensive home purchases on the Bandra seafront.
This is not Singh’s first major real estate purchase, having bought a 3,413 square foot apartment in Bandra’s Satguru Rendezvous project for Rs 33 crore in 2023. Other members of the Alkem family have also made significant property purchases, including Seema Singh, who bought a penthouse at Lodha Sea Face in Worli for Rs 185 crore in December 2024.
Mumbai’s luxury property market has witnessed several high-value transactions in recent months, including SR Menon Properties LLP’s purchase of a 14,866 square foot apartment for Rs 187 crore in Lodha Sea Face, Amit Rathi’s purchase of a home valued at Rs 89.91 crore in Palais Royale, and Aruna Varma’s purchase of a luxurious apartment in Worli for Rs 68 crore.
The demand for luxury properties in Mumbai is driven by the city’s status as a financial hub and the increasing wealth of its residents. Developers are catering to this demand by building ultra-luxury properties with high-end amenities and stunning views. Sunny Bijlani, Joint Managing Director of Supreme Universal, the developers of Supreme ArtHouse, noted that the company’s focus on ultra-luxury properties has paid off, with the recent sale being the largest of its kind on the Bandra seafront.
Alkem Laboratories, where Sarvesh Singh is an executive director, is a leading Indian pharmaceutical company with a global presence. The company’s success has enabled its executives to invest in luxury properties, contributing to the growth of Mumbai’s high-end property market. Overall, the luxury property market in Mumbai is expected to continue to thrive, driven by the city’s economic growth and the increasing demand for high-end properties.
Alkem Laboratories has finalized the purchase of a 100% ownership stake in Adroit Biomed.
Alkem Laboratories, a leading pharmaceutical company, has successfully completed the acquisition of a 100% stake in Adroit Biomed, a biotechnology company. This strategic move is expected to strengthen Alkem’s presence in the biotechnology sector and expand its product portfolio.
Adroit Biomed is a research-based organization that focuses on developing innovative products and solutions for various therapeutic areas. The company has a strong research and development pipeline, with several products in different stages of development. With this acquisition, Alkem Laboratories will gain access to Adroit Biomed’s research capabilities, product portfolio, and expertise in biotechnology.
The acquisition is expected to enhance Alkem’s competitiveness in the global pharmaceutical market and provide new opportunities for growth. Alkem Laboratories has been expanding its product portfolio and capabilities through strategic acquisitions and partnerships. This acquisition is a significant step towards achieving the company’s goal of becoming a leading player in the biotechnology sector.
The terms of the acquisition were not disclosed, but it is expected to be completed in a phased manner. Alkem Laboratories will integrate Adroit Biomed’s operations and personnel into its existing business, with the aim of maximizing synergies and minimizing disruptions.
The acquisition of Adroit Biomed is part of Alkem Laboratories’ strategy to expand its presence in the biotechnology sector and to diversify its product portfolio. The company has been investing heavily in research and development and has established partnerships with various organizations to develop new products and technologies.
The completion of this acquisition is a significant milestone for Alkem Laboratories and is expected to have a positive impact on the company’s future growth and profitability. With the acquisition of Adroit Biomed, Alkem Laboratories has strengthened its position in the biotechnology sector and is well-positioned to capitalize on the growing demand for biotechnology products and services.
The acquisition is also expected to benefit Adroit Biomed’s employees, customers, and partners, as it will provide them with access to Alkem Laboratories’ global network, resources, and expertise. Overall, the acquisition of Adroit Biomed by Alkem Laboratories is a strategic move that is expected to drive growth, innovation, and success for both companies.
Biosimilar denosumab, Alkem’s Denuril, Demonstrates Comparable Efficacy in Treating Postmenopausal Osteoporosis
A recent study has demonstrated that Biosimilar Denosumab (Denuril), manufactured by Alkem, is comparable in efficacy to the original Denosumab in treating postmenopausal osteoporosis. Denosumab is a monoclonal antibody that helps to prevent bone loss by inhibiting the activity of osteoclasts, which are cells that break down bone. It is commonly used to treat osteoporosis in postmenopausal women.
The study, published in the Journal of Bone and Mineral Research, involved 354 postmenopausal women with osteoporosis who were randomized to receive either Biosimilar Denosumab (Denuril) or the original Denosumab. The participants received 60mg of the study drug every six months for one year.
The results of the study showed that both Biosimilar Denosumab (Denuril) and the original Denosumab significantly increased bone density in the spine and hip, and reduced the risk of vertebral fractures, a common complication of osteoporosis. The efficacy of the two medications was comparable, with no significant differences observed between the two groups.
The study also found that both medications were well tolerated, with similar levels of adverse events reported in both groups. The most common side effects were mild and included injection site reactions, pain, and infections.
The authors of the study concluded that Biosimilar Denosumab (Denuril) is a viable option for the treatment of postmenopausal osteoporosis, offering similar efficacy and safety to the original Denosumab. This could lead to cost savings and increased access to treatment for patients, making it a valuable addition to the treatment options for osteoporosis.
Overall, the study provides reassuring evidence for the use of Biosimilar Denosumab (Denuril) in the treatment of postmenopausal osteoporosis, and supports its adoption as a viable alternative to the original Denosumab.
Alkem Labs completes inspection process at Taloja Center
The article reports that Alkem Labs, a leading generic pharmaceutical company, has concluded an inspection at its Taloja Center facility. The inspection was conducted by the United States Food and Drug Administration (USFDA). The purpose of the inspection was to verify and assess the compliance of Alkem Labs’ manufacturing facilities, processes, and testing procedures with the current Good Manufacturing Practices (cGMPs) guidelines.
The inspection, which took place over a period of several days, aimed to ensure that Alkem Labs’ Taloja Center facility is adhering to the highest standards of quality, safety, and efficacy in the production and testing of pharmaceutical products. The inspectors assessed various aspects of the company’s operations, including the manufacturing, processing, and testing of its products, as well as the company’s record-keeping and documentation practices.
The inspection is a significant milestone for Alkem Labs, as it demonstrates the company’s commitment to ensuring the quality and safety of its products, as well as its compliance with international regulatory standards. Alkem Labs has built a strong reputation for its high-quality products and robust manufacturing processes, and this inspection is a further testament to its dedication to quality and customer satisfaction.
The outcome of the inspection is still pending, but Alkem Labs has reported that it has “full co-operation and support” from the USFDA during the inspection process. This suggests that the company is committed to working closely with the regulatory authorities to ensure its compliance and to address any issues that may arise.
In conclusion, the inspection by the USFDA at Alkem Labs’ Taloja Center facility is an important step towards ensuring the quality and safety of the company’s products. As a leading generic pharmaceutical company, Alkem Labs has a significant responsibility to its customers, patients, and regulatory authorities to maintain the highest standards of quality and compliance. This inspection is a crucial step in upholding that responsibility.
Alkem Laboratories’ Bioequivalence Center achieves clean record with US FDA inspection, passing with zero observations.
Alkem Laboratories, a leading pharmaceutical company in India, has announced that its Bioequivalence Center has successfully cleared a inspection by the United States Food and Drug Administration (USFDA) without any observations. This achievement is a significant milestone for the company, demonstrating its commitment to maintaining the highest standards of quality and regulatory compliance.
The USFDA inspection was conducted to ensure that Alkem’s Bioequivalence Center, which is responsible for testing and evaluating the bioequivalence of pharmaceutical products, meets the regulatory requirements of the FDA. The inspection covered various aspects, including the center’s infrastructure, equipment, processes, and personnel.
Alkem Laboratories’ Bioequivalence Center is equipped with state-of-the-art facilities and cutting-edge technology, enabling it to conduct complex bioequivalence studies for a wide range of pharmaceutical products. The center is staffed by a team of experienced professionals who are well-versed in the latest regulatory requirements and industry best practices.
The successful inspection by the USFDA is a testament to the center’s ability to maintain high-quality standards and adhere to regulatory guidelines. This achievement is a significant boost to the company’s reputation and allows it to offer its services to clients in the pharmaceutical industry with confidence.
Alkem Laboratories is committed to sustaining its reputation for quality and compliance, and this achievement is a reflection of its dedication to meeting the stringent requirements of the USFDA. The company’s Bioequivalence Center has been recognized for its expertise and capabilities, and this inspection success is a major milestone in its journey to become a leading provider of bioequivalence testing services in the global pharmaceutical industry.
The news is a significant development for Alkem Laboratories, which has been working to expand its presence in the global pharmaceutical industry. The company has been making concerted efforts to invest in its research and development capabilities, as well as its manufacturing infrastructure, to meet the growing demand for high-quality pharmaceutical products.
In conclusion, Alkem Laboratories’ Bioequivalence Center’s successful inspection by the USFDA without any observations is a significant achievement, demonstrating the company’s commitment to quality and regulatory compliance. This achievement is likely to enhance the company’s reputation and credibility in the pharmaceutical industry, and it is expected to open up new opportunities for the company to expand its offerings and reach new markets.
India sees a significant decrease in the price of a commonly used diabetes medication following the introduction of generic alternatives.
The price of the diabetes drug empagliflozin, also known as Jardiance, has been significantly reduced by almost one-tenth in India. The drug, developed by German pharma giant Boehringer Ingelheim, is used to control blood sugar levels in patients with type 2 diabetes. The original price of the drug was around Rs 60 per tablet, but with the entry of its generic versions in the market, it is now available for as low as Rs 5.5 per tablet.
Mankind, Alkem, and Glenmark Pharmaceuticals have launched generic versions of empagliflozin, with prices starting from Rs 5.49 per tablet for the 10 mg variant. These prices are nearly 80% lower than the original price of the innovator product. The generic versions of the drug come with additional features, such as anti-counterfeit security bands, patient education information, and QR codes that provide prescribing information and additional patient education.
The launch of these generic versions of empagliflozin is a significant step in making the drug more affordable for millions of Indians who are suffering from type 2 diabetes. India is known as the diabetes capital of the world, with over 10 crore people diagnosed with the disease, according to the Indian Council of Medical Research–India Diabetes (ICMR INDIAB) study in 2023. Reducing the cost of anti-diabetes medicines like empagliflozin is a crucial step in tackling the disease burden in the country.
Sikkim Governor Unveils Community Hall in Pakyong, Flags Off Sulabh Alkem Award 2024
The Sulabh Alkem Award 2024 ceremony was held at the Integrated Multipurpose Hall in Pakyong, Sikkim, where Governor Om Prakash Mathur attended as the chief guest. The event recognized the outstanding contributions of individuals and institutions to sanitation and hygiene under Project AagazPlus, an initiative aimed at promoting accessible and hygienic sanitation in schools, with a focus on girls’ education and empowerment. The project integrates hygiene improvement in schools through practices such as handwashing with soap, access to clean drinking water, and use of improved sanitation facilities.
Governor Mathur emphasized the importance of hygiene and sanitation, praising the Sulabh Sanitation Club and Alkem Foundation for their efforts in introducing Project AagazPlus to schools. He highlighted the need for initiatives that foster healthier lifestyles among students. The Governor also inaugurated the Integrated Multipurpose Community Hall, a CSR project by the Airports Authority of India.
The event featured testimonials from various stakeholders, including students and teachers, who shared their positive experiences with the project. The Sulabh Alkek Award 2024 recognized schools, teachers, and volunteers for their outstanding work in promoting WASH (water, sanitation, and hygiene) initiatives under Project AagazPlus. Some of the award winners included Government Secondary School, Dalapchand, and teachers Ruchi Thapa, Aquino Sharma, Karma Kunsang Tamang, and Santosh Chettri. The awards also recognized volunteers Ayesha Khatun, Ayogita Sharma, and Ayush Thapa.
Overall, the event aimed to promote better hygiene and sanitation practices in schools, and the importance of girls’ education and empowerment. The award ceremony also acknowledged the efforts of various stakeholders, including the Sulabh Sanitation Club, Alkem Foundation, and the Education Department, in promoting WASH initiatives in schools.
This popular diabetes medication is set to get a significant price cut, dropping from Rs 60 to just Rs 9 per unit.
The cost of Empagliflozin, a crucial drug for managing diabetes and its associated conditions, is set to drop significantly in India. The price of the medicine, which was previously around Rs 60 per tablet, will be reduced to just Rs 9 per tablet, making it more accessible to millions of diabetes patients in the country. This development comes after the patent for the drug, which was previously held by German pharmaceutical company Boehringer Ingelheim, expired on March 11.
As a result, Indian pharmaceutical companies such as Mankind Pharma, Torrent, Alkem, Dr. Reddy, and Lupin will be able to introduce their own versions of the drug, offering patients cheaper alternatives. Mankind Pharma, for example, plans to offer the drug at a price 90% lower than the innovator company, making it more affordable for patients.
Empagliflozin plays a crucial role in preventing heart failure and delaying kidney failure, making it a vital medication for those with diabetes. However, its high cost has previously made it difficult for many to access. The introduction of more affordable options from Indian companies is expected to bring significant benefits to millions of patients.
The reduced price of Empagliflozin is poised to provide much-needed financial relief to diabetes patients, who often face the burden of out-of-pocket medication expenses. In India, over 10.1 crore people are living with diabetes, and limited insurance coverage often leaves patients to shoulder medication costs independently. The availability of more affordable options is expected to make a significant difference in the lives of these patients.
The economic burden of diabetes in India is substantial, and the reduced price of Empagliflozin is a welcome development for diabetic patients across the country. With the introduction of more affordable alternatives, millions of patients will have access to a vital medication, allowing them to better manage their condition and improve their overall health.